Asian Pacific Journal of Cancer Prevention

  • 제13권10호
  • /
  • Pages.5161-5165
  • /
  • 2012
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Expression of Smad7 in Cholangiocarcinoma: Prognostic Significance and Implications for Tumor Metastasis

  • Huang, Qiang (Department of General Surgery, the Affiliated Provincial Hospital of Anhui Medical University) ;
  • Liu, Lei (Department of General Surgery, the Affiliated Provincial Hospital of Anhui Medical University) ;
  • Liu, Chen-Hai (Department of General Surgery, the Affiliated Provincial Hospital of Anhui Medical University) ;
  • Shao, Feng (Department of General Surgery, the Affiliated Provincial Hospital of Anhui Medical University) ;
  • Xie, Fang (Department of General Surgery, the Affiliated Provincial Hospital of Anhui Medical University) ;
  • Zhang, Chuan-Hai (Department of General Surgery, the Affiliated Provincial Hospital of Anhui Medical University) ;
  • Hu, San-Yuan (Department of General Surgery, Qilu Hospital of Shandong University)
  • 발행 : 2012.10.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: There are few molecular markers known to predict cholangiocarcinoma (CCA) prognosis. Smad7 has a certain relationship with epithelial-mesenchymal transition (EMT), but its relevance to CCA in unclear. Therefore expression and clinical significance of Smad7 in CCA was the focus of this study. Methods: Expression of Smad7, E-cadherin and vimentin was assessed in 41 patients with CCA by immunohistochemistry and analyzed for associations with clinical parameters. Results: Smad7 and vimentin expression in the CCA tissue was dramatically higher than that in adjacent tissues. In addition, Smad7, vimentin and E-cadherin expression was significantly associated with CCA lymph node metastasis and perineural invasion($P{\leq}0.05$), but not other factors, such as gender, age, tumor location, tumor type and tumor differentiation degree (P>0.05). The overall survival and relapse-free survival rate was significantly higher in patients with negative Smad7 expression than those with positive Smad7 expression. Conclusion: EMT phenomena may occur in the process of CCA invasion and metastasis. Smad7, which was highly expressed in CCA, may be considered to be one feedback regulator in late stages and could have potential as a prognostic indicator for clinical assessment.

키워드

참고문헌

  1. Aljiffry M, Walsh M J, Molinari M (2009). Advance in diagnosis,treatment and palliation of cholangiocarcarcinoma: 1990-2009. World J Gastrointestinal, 15, 4240-62. https://doi.org/10.3748/wjg.15.4240
  2. Chen YK, Huang AH, Cheng PH, et a1(2012). Overexpression of Smad proteins, especially Smad7, in oral epithelial dysplasias. Clin Oral Investig, 6, 6.
  3. Dahler AL, Cavanagh LL, Saunders NA (2001). Suppression of keratinocyte growth and differentiation by transforming growth factor beta1 involves multiple signaling pathways. J Invest Dermatol, 116, 266-74. https://doi.org/10.1046/j.1523-1747.2001.01243.x
  4. Drabsch Y, Ten Dijke P (2012). TGF-${\beta}$ signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev, 7, 20.
  5. Gratchev A, Kzhyshkowska J, Kannookadan S, et a1 (2008). Activation of a TGF-beta-specific multistep gene expression program in mature macrophages requires glucocorticoidmediated surface expression of TGF-beta receptor II. J Immunol, 180, 6553-65. https://doi.org/10.4049/jimmunol.180.10.6553
  6. Halder SK, Rachakonda G, Deane NG, et a1 (2008). Smad7 induces hepatic metastasis in colorectal cancer. Brit J Cancer, 4, 957-65.
  7. Hayashi H, Abollah S, Qiu Y, et al (1997). The MAD-related protein Smad7 associates with the TGF-beta receptor and functions as an antagonist of TGF-beta signaling. Cell, 89, 1165-73. https://doi.org/10.1016/S0092-8674(00)80303-7
  8. Iiizumi M, Liu W, Pai SK, et al (2008). Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy. Biochim Biophys Acta, 1786, 87-104.
  9. Iwatsuki M, Mimori K, Yokobori T, et al (2010). Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci, 101, 293-9. https://doi.org/10.1111/j.1349-7006.2009.01419.x
  10. Kalluri R, Weinberg RA(2009). The basics of epithelial-mesenchymal transition. J Clin Invest, 119, 1420-8. https://doi.org/10.1172/JCI39104
  11. Kim YH, Lee HS, Lee HJ, et a1 (2004). Prognostic significance of the expression of Smad4 and Smad7 in human gastric carcinomas. Ann Oncol, 15, 574-80. https://doi.org/10.1093/annonc/mdh131
  12. Kleeff J, Ishiwata T, Maruyama H , et al(1999). The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene, 18, 5363-72. https://doi.org/10.1038/sj.onc.1202909
  13. Kokkinos MA, wafai R, Wong MK, et al (2007). Vimentin and epithelial-mesenchymal transition in human breast cancer-observations in vitro and in vivo. Cells Tiss Organs, 185, 191-203. https://doi.org/10.1159/000101320
  14. Lan HY, Chung AC (2011). Transforming growth factor-${\beta}$ and Smads. Contrib Nephrol, 170, 75-82. https://doi.org/10.1159/000324949
  15. Leng A, Liu T, He Y, Li Q, Zhang G (2009). Smad4/Smad7 balance: A role of tumorigenesis in gastric cancer. Exp Mol Pathol, 87, 48-53. https://doi.org/10.1016/j.yexmp.2009.03.003
  16. Li H, Qin Y, Cui Y, et al (2011). Analysis of the surgical outcome and prognostic factors for hilar cholangiocarcinoma: a Chinese experience. Dig Surg, 28, 226-31. https://doi.org/10.1159/000327361
  17. Li Y, Wang JP, Santen RJ, et al (2010). Estrogen stimulation of cell migration involves multiple signaling pathway interactions. Endocrinology, 151, 5146-56. https://doi.org/10.1210/en.2009-1506
  18. Liu Q, Zhang Y, Mao H, et a1 (2012). A crosstalk between the Smad and JNK signaling in the TGF-${\beta}$-induced epithelialmesenchymal transition in rat peritoneal mesothelial cells. PLoS One, 7, e32009. https://doi.org/10.1371/journal.pone.0032009
  19. Moustakas A, Heldin CH (2007). Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci, 98, 1512-20. https://doi.org/10.1111/j.1349-7006.2007.00550.x
  20. Nakajima S, Doi R, Toyoda E, et al (2004). N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clin Cancer Res, l0, 4125-33.
  21. Neilson EG (2006). Mechanisms of disease: Fibroblasts-a new look at an old problem. Nat Clin Pract Nephrol, 2, 101-8. https://doi.org/10.1038/ncpneph0093
  22. Park YN, Chae KJ, Oh B K, et al (2004). Expression of Smad7 in hepatocellular carcinoma and dysplastic nodules: resistance mechanism transforming growth factor-beta. Hepatogastroenterology, 51, 396-400.
  23. Peinado H, Olmeda D, Cano A (2007). Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer, 7, 415-28. https://doi.org/10.1038/nrc2131
  24. Pittman AM, Naranjo S, Webb E, et al(2009). The colorectal cancer risk at 18q21 is caused by a novel variant altering SMAD7 expression. Genome Res, 19, 987-93. https://doi.org/10.1101/gr.092668.109
  25. Polette M, Mestdagt M, Bindels S, et al (2007). Beta-catenin and ZO-1: shuttle molecules involved in tumor invasionassociated epithelial-mesenchymal transition processes[J]. Cells Tiss Organs, 185, 61-5. https://doi.org/10.1159/000101304
  26. Sabe H (2011). Cancer early dissemination: cancerous epithelial-mesenchymal transdifferentiation and transforming growth factor ${\beta}$ signalling. J Biochem, 149, 633-9. https://doi.org/10.1093/jb/mvr044
  27. Sandusky G, Berg DT, Richardson MA, et al (2002). Modulation of thrombomodulin-dependent activation of human protein C through differential expression of endothelial Smads[J]. J Biol Chem, 277, 49815-9. https://doi.org/10.1074/jbc.C200543200
  28. Sethi S, Sarkar FH, Ahmed Q, et al (2011). Molecular markers of epithelial-to-mesenchymal transition are associated with tumor aggressiveness in breast carcinoma. Transl Oncol, 4, 222-6. https://doi.org/10.1593/tlo.10244
  29. Yu H, Zhao G, Li H, et al (2012). Candesartan antagonizes pressure overload-evoked cardiac remodeling through Smad7 gene-dependent MMP-9 suppression. Gene, 1, 3.
  30. Zhu HJ, Iaria J, Sizeland AM(1999). Smad7 differentially regulates transforming growth factor beta-mediated signaling pathways. J Biol Chem, 274, 32258-64. https://doi.org/10.1074/jbc.274.45.32258
  31. Zhu L, Wang L, Wang X, et al (2011). Hepatic deletion of Smad7 in mouse leads to spontaneous liver dysfunction and aggravates alcoholic liver injury. PLoS One, 6, e17415. https://doi.org/10.1371/journal.pone.0017415

피인용 문헌

  1. Novel diagnostic and prognostic biomarkers in biliary tract cancer vol.7, pp.5, 2013, https://doi.org/10.1517/17530059.2013.826646
  2. Prognostic Biomarkers in Patients with Resected Cholangiocarcinoma: A Systematic Review and Meta-analysis vol.21, pp.2, 2014, https://doi.org/10.1245/s10434-013-3286-x
  3. Molecular diagnosis of intrahepatic cholangiocarcinoma vol.22, pp.2, 2014, https://doi.org/10.1002/jhbp.156
  4. Expression of BAMBI and its combination with Smad7 correlates with tumor invasion and poor prognosis in gastric cancer vol.35, pp.7, 2014, https://doi.org/10.1007/s13277-014-1962-5
  5. SMAD7: a timer of tumor progression targeting TGF-β signaling vol.35, pp.9, 2014, https://doi.org/10.1007/s13277-014-2203-7
  6. Integrative Analysis of Transcriptional Regulatory Network and Copy Number Variation in Intrahepatic Cholangiocarcinoma vol.9, pp.6, 2014, https://doi.org/10.1371/journal.pone.0098653
  7. Clinicopathological Significance of Osteopontin in Cholangiocarcinoma Cases vol.17, pp.1, 2016, https://doi.org/10.7314/APJCP.2016.17.1.201
  8. MicroRNA-182 targets SMAD7 to potentiate TGFβ-induced epithelial-mesenchymal transition and metastasis of cancer cells vol.7, pp.2041-1723, 2016, https://doi.org/10.1038/ncomms13884
  9. GP73 promotes invasion and metastasis of bladder cancer by regulating the epithelial-mesenchymal transition through the TGF-β1/Smad2 signalling pathway vol.22, pp.3, 2018, https://doi.org/10.1111/jcmm.13442